Introduction
Cystic fibrosis (CF) is among the most common genetic diseases. Despite considerable improvement in survival recently with conventional therapies, patients with CF become increasingly debilitated and have markedly shortened life expectancies, mostly because of recurrent pulmonary infections.
The genetic defect in CF is well documented: mutations in a cell membrane chloride channel and the cystic fibrosis transmembrane conductance regulator (CFTR). The resulting defective cellular chloride transport has many consequences. CF patients produce very viscous mucous, the key consequences of which are exocrine pancreatic insufficiency and recurrent pulmonary infections. The latter leads to respiratory failure. 1, 2 Treatment to date has generally been supportive: replacing the function of the defective ion channel has not yet been possible with small molecule therapeutics.
Gene therapy would seem to offer a potentially useful therapeutic approach. However, despite great effort, CFTR gene delivery to the lungs has not yet succeeded in altering the course of the disease. [3] [4] [5] [6] [7] [8] CF presents many obstacles to gene delivery that explain this situation. These include uncertainty as to which are the most appropriate cellular target for gene delivery, the best route of administration, viscous, neutrophil-, and bacteria-rich mucous that both degrades vectors and prevents vectors delivered through the airways from reaching target epithelial cells, antigenicity of gene delivery vehicles, and the potential need to repeat gene delivery to compensate for loss of vector DNA and turnover of transduced cells. [9] [10] [11] Recombinant SV40-derived gene delivery vehicles (rSV40s) may help overcome some of these obstacles. These vectors integrate into the cell genome to provide permanent transduction and transduce most cell types very efficiently. 12, 13 Perhaps, most importantly, because their mode of entry into cells bypasses the antigen processing apparatus, 14, 15 and because they thereafter produce no proteins of viral origin, rSV40s do not elicit detectable immune responses-neither neutralizing antibodies nor cell-mediated immunity. Uniquely, among gene delivery vectors, rSV40s can be administered repeatedly without loss of transduction efficiency to normal immunocompetent individuals. 16 Despite considerable effort, genetic therapy for CF remains elusive. Some difficulties encountered in achieving this quest reflect the inherent pathophysiology of CF, whereas others are due to limitations of gene delivery technology. Application of rSV40s to this disease may circumvent some of these obstacles, for example the lack of neutralizing antibodies against these vectors may facilitate a potential need for repeated administration. To accommodate the large CFTR cDNA, we had to remove not only SV40 Tag genes, but also all capsid genes. We, therefore, tested whether 'gutless' rSV40s could be packaged, whether they could express and carry a functional coding region for human CFTR cDNA, and provide an active chloride channel to CFTR-negative cells. Our data show that such gutless rSV40 vectors are easily produced by COS-7 cells at very high titers, without helper virus or repeated cotransfection.
The current studies, undertaken in vitro, were designed to test whether SV40-derived vectors could accommodate the CFTR cDNA, deliver it to cells, and provide a functional chloride channel. These vectors deliver CFTR expression efficiently to unselected CFTRnegative target cells. The resulting CFTR protein localizes to the cell membranes and provides functional chloride channels and direct evidence of a corrective effect in vitro. Furthermore, these studies led to the testing of the vector in a mouse model of CFTR-related disease, in which the vector was able to attenuate and in some cases resolve airway inflammation associated with intra-tracheal bacterial instillation.
Results
Making rSV40-CFTR rSV40 genome constructs reported to date lacked the 2.6 kb Tag and tag genes, but retained 2 kb containing the SV40 capsid genes, VP1, VP2, and VP3. As wild type SV40 (wtSV40) genome is 5.25 kb, deletion of additional SV40 sequences should allow effective packaging of a vector carrying a 4.2 kb version of the human CFTR cDNA. This is shown in Figure 1 . Briefly, pSV5 contains a Tag-deleted SV40 genome with two tandem SV40 early promoters (SV40-EP) followed by an engineered polylinker. This modified SV40 genome was cloned as a NotI fragment into pGEM13. An additional 1.8 kb of wtSV40 DNA was excised from pSV5 as a HpaI fragment to produce pSV5(4.3). Human CFTR cDNA was cloned into the polylinker and rSV40-CFTR was produced from this plasmid according to published procedures. 17 Efficiency of transduction by rSV40-CFTR and localization of the delivered CFTR protein at the cell membrane CFPAC cells (CFPAC-1, ATCC) make a mutated form of CFTR that is folded incorrectly (deletion of three nucleotides resulting in a phenylalanine-508 deletion), does not reach the cell membrane, and so is more rapidly degraded than wt CFTR. 18 We, therefore, used these cells to determine the efficiency of rSV40-CFTR transduction and subcellular localization of the delivered protein. CFPAC cells were transduced with rSV40-CFTR or rSV40-HBS, or were mock transduced. They were then examined by fluorescence microscopy after immunostaining with antibody to CFTR (Figure 2a ). Transduction efficiency, allowing for some cell-to-cell variation in levels of transgene expression, was 85-90% in unselected cells. Higher magnification analysis ( Figure 2b ) suggested localization of the immunodetectable CFTR along the cellular membrane.
Therefore, to evaluate more definitively the subcellular localization of the rSV40-CFTR delivered protein, confocal microscopic studies were done. Again, CFPAC cells were transduced with rSV40-CFTR or rSV40-HBS, or mock transduced, then immunostained for CFTR and viewed using a confocal microscope ( Figure 2c ). These studies confirmed that the delivered CFTR localized along the cell membrane. Distribution of the protein was patchy, as has been reported by others. 19 Functional correction of CFTR chloride-channel defect with rSV40-CFTR An important measurable activity of CFTR is its function as a cell membrane chloride channel. To test whether rSV40-CFTR transduction of CFPAC cells produced a functional chloride channel, two different assays were used. In the first series of studies, mock-and rSV40-CFTRtransduced cells were loaded with the fluorescent Clsensitive dye, N-(6-methoxyquinolyl) acetoethyl ester (Sigma Chemical Co.), 20 and stimulated by 10 mM forskolin. Permeability to Cl was assayed as a change in fluorescence as a function of time after adding forskolin. Compared with TC7 cells (CFTR+ normal monkey kidney cells, +control) and mock-transduced CFPAC cells (Àcontrol), rSV40-CFTR restored Cl-channel activity in CFPAC cells to B50% of wt levels ( Figure 3) .
As an additional test of whether rSV40-CFTR could deliver a functional Cl channel and to determine whether channel activity could be restored in a different cell line, we performed 36 Cl isotope tracer efflux assays on IB3-1 cells. CFTR-mutant IB3-1 cells (genotype DF508/ W1282X) were infected with rSV40-CFTR at an MOI of 100. Mock-transduced T84 cells were the CFTR+ control, mock-transduced IB3 cells were the CFTR-control. On day 10 post-transduction, the cells were loaded with 5 mCi of 36 Cl for 5 h, and washed to remove excess isotope. The efflux rate was then measured at 30 s intervals for 4.0 min. After the final time point, the monolayer was carefully examined for integrity. Flasks with non-intact monolayers were eliminated from the experiment. Samples were counted for Cl 36 activity. Transduction with rSV40-CFTR significantly increased Cl-channel activity by this assay, delivering B33% of wt Cl-channel activity (P ¼ 0.01), as compared with control T84 cells ( Figure 4 ).
In vivo correction of the mouse CF lung phenotype with rSV40-CFTR
Having determined the functional expression of the CFTR channel in vitro, it was necessary to determine whether the delivery of a functional chloride channel with rSV40 vectors would also have beneficial effects on a CF lung disease phenotype. Therefore, we used our in vitro characterized vectors to deliver the CFTR gene to CftrÀ/À mice that were used to recapitulate a wellcharacterized Pseudomonas aeruginosa (PA01 strain) agarose-bead airway challenge model. 21 Two sets of independent experiments were performed with this model. In the initial Pseudomonas-bead challenge experiment, matched groups of five CftrÀ/À mice Restoring a functional Cl channel with rSV40(CFTR) C Mueller et al were treated with 4.0 Â 10 7 particles of either rSV40-CFTR vector or the irrelevant rSV40-bilirubin uridine diphosphate glucuronoside transferase (BUGT)-negative control through intra-tracheal injection and housed in specific pathogen-free conditions. Owing to the highly stable expression of rSV40 vectors, it was possible to allow the mice to completely heal from the rSV40 intra-tracheal injection before performing the second intra-tracheal injection with the Pseudomonas-bead slurry. Thus, 8 weeks later, the mice were challenged with 30 ml of a 50% P. aeruginosa (PA01) agarose-bead slurry (as determined by 30 min gravity sedimentation), as described previously. 21, 22 This initial bead preparation had a bacterial count of 3.8 Â 10 6 cfu ml -1 and resulted in the previously characterized excessive weight loss in CftrÀ/À mice. Interestingly, in our studies, mice rescued with rSV40-CFTR had statistically significant less weight loss on the first 3 days after the bacterial challenge ( Figure 5 ) when compared to rSV40-BUGT-treated mice. On the last and fourth day before killing, rSV40-CFTR rescued mice also showed a trend toward less weight loss (P ¼ 0.06). The hallmark end point of this model has been the excessive weight loss seen in CftrÀ/À mice observed in earlier studies. 21 In our experiments the day 3 weight loss difference between rSV40-BUGT-treated mice (26%) and rSV40-CFTR-rescued mice (19%) was approximately 7% ( Figure 5 ).
To determine whether these differences in weight lose were consistent with CFTR expression, RT-PCR assays to detect the SV40-driven human CFTR transcript were performed on lung tissue collected 4 days after bacterial challenge. As shown in Figure 6 , human CFTR expression was detected in mice receiving the rSV40-CFTR, whereas none was detectable by RT-PCR in mice receiving the BUGT vector. RT-PCR using a no reverse transcriptase control to rule out the possibility of rSV40-CFTR DNA amplification was negative (data not shown). It should be noted that this expression is representative of mice approximately 9 weeks post-rSV40-CFTR intratracheal delivery and after they have undergone pseudomonas agar-bead challenges, thus highlighting the stability of transgene expression achieved by rSV40 gene delivery. This stability is further evidence by a separate experiment in which IHC analysis of lung tissues from mice receiving an AU1 epitope tagged rSV40 vector killed at 2, 4, and 9 weeks post-delivery showed no apparent decrease in the expression of the epitope tag at Figure 1 Construction of rSV40-CFTR. pSV5 carries an SV40 genome from which the Tag gene was deleted and replaced by a second SV40-EP plus a polylinker. The resulting Tag-less rSV40 genome, which is carried in pGEM13 (Promega), has been described. 12 Restoring a functional Cl channel with rSV40(CFTR) C Mueller et al the various time points (data not shown). Further analysis of the mice 9 weeks post-delivery revealed that rSV40 transduction as determined by AU1 epitope expression was evident throughout the airways including in mucous-producing cells, as determined by overlay of AUI expressing cells and the lysozyme expressing mucous-producing cells (Figure 7 ). It has been previously reported that lysozyme is produced by submucosal glands and goblet cells. 23, 24 Further analysis of the lung compartment of Pseudomonas-bead challenged mice revealed that rSV40mediated correction of the CftrÀ/À mice, not only attenuated the weight loss phenotype, but it had also had an effect on the inflammatory cytokine profiles recovered from the broncho-alveolar lavages (BALs). Although the cytokine levels in rSV40-CFTR-rescued mice all trended lower, IL-1beta was statistically significantly lower ( Figure 8 ). Also importantly for CF-related lung disease, there was a strong trend (Pp0.1) towards lower KC levels in treated mice. KC is considered the mouse analog to IL-8 and is mainly responsible for the recruitment of neutrophils into the lung.
To determine whether this attenuated inflammatory profile in the BALs of rSV40-CFTR-recued mice was accompanied by a reduction in the influx of neutrophils and lung pathology, a second set of aged-matched mice were IT injected with either rSV40-CFTR or rSV40-BUGT. As in the first experiment described above, 8 weeks after rSV40 delivery, mice were challenged with Ps-bead slurry, albeit of a slightly lower cfu count because of preparation variations (3.0 Â 10 6 cfu ml -1 ). Histopathological analysis of lung sections from this second cohort showed a dramatic reduction in the infiltration and inflammation of the lung tissue ( Figures 9 and 10 ). Mice treated with the control vector showed severe inflammatory infiltration of the airways with focal disease in the parenchyma, often accompanied with epithelial disintegration and sloughing. This was accompanied by a prominent presence of neutrophils and type II pneumocyte hyperplasia. These findings were highly attenuated in rSV40-CFTR-treated animals; the statistically significant magnitude of these changes can be appreciated in the inflammatory scores obtained from an independent blinded pathologist ( Table 1 ). As 
Discussion
These studies were designed to test whether 'gutless' rSV40 vectors carrying human CFTR cDNA could be effectively packaged and deliver CFTR expression after transduction, and whether the CFTR so provided constituted a functional chloride channel. It was important to ascertain that 'gutless' rSV40 vectors carrying the 4.2 kb CFTR cDNA insert could be packaged by COS-7 cells. rSV40-CFTR was packaged by COS-7 cells at yields comparable to those obtained for other rSV40s that carry capsid genes: B1011 IU ml -1 . Thus, the size of the vector genome, 5.5 kb, was within the packaging limits of this system. Some other vector systems require simultaneous cotransfection of packaging cells with multiple plasmids, or coinfection with helper viruses, to produce gutless vectors, but the effective packaging of a rSV40 lacking capsid genes in COS-7 cells indicates that the packaged rSV40 genomes need not carry SV40 capsid genes. The latter are expressed adequately, driven by their own promoter, by the COS-7 cells: neither helper virus nor cotransfection is involved. Preliminary studies show that SV40 capsid genes, under the control of the SV40 late promoter, are not expressed constitutively in COS-7 cells, but that the presence of a replicating rSV40 genome that includes the late promoter is sufficient to activate COS-7 transcription of the capsid genes in trans (M. Mariere and D.S. Strayer, unpublished data). Figure 4 Changes in 36 Cl efflux show CFTR-channel activity in response to agonist stimulation of IB3 cells transduced with rSV40-CFTR. 36 Cl isotope tracer efflux assays-IB3 cells were plated at a density of 2 Â 10 6 into T-25 flasks in LHC-8 media containing 10% FBS and 5% penicillin/streptomycin (LHC-8+) and allowed to grow overnight. The next day, the media was changed with 10 ml of fresh LHC-8+ and cells were infected with rSV40-CFTR virus at an MOI of 100. Samples were mixed with CytoSafe scintillation fluid and counted for 36 Cl activity. The percentage of change from the maximal post-agonist rate (c.p.m.) and the minimal rate (c.p.m.) before that efflux event is defined as the 'percentage of change in efflux' (max post-agonist % efflux À min pre-agonist % efflux). Cells without significant CFTR activity will not stimulate on exposure to agonist mixture and will display a negative 'percentage of change in efflux'. Uninfected negative control IB3 cells ('IB3'), supra-physiologic CFTR-positive control T-84 cells, and IB3 cells infected with rSV40-CFTR are shown; t-test P-values are relative to IB3-negative control cells. Restoring a functional Cl channel with rSV40(CFTR) C Mueller et al A possible explanation for this phenomenon is that replicating SV40 genomes titrate out a cellular repressor that inhibits transcription of integrated SV40 late genes. 25 In our system, then, the rSV40 genome replicating in COS-7 cells would bind the cellular repressor and, in so doing, trans-activate the SV40 promoter to drive expression of the capsid genes. Replicating rSV40 genomes would then de-repress expression of SV40 capsid genes from the integrated copy of the wt SV40 genome in COS-7 cells. Thus, rSV40s do not need to carry SV40 capsid Figure 6 Stable expression of CFTR in mouse lungs after intratracheal delivery of rSV40-CFTR. RT-PCR for Human CFTR mRNA was assayed from lungs 4 days after pseudomonas challenge. Lungs were homogenized and RNA was extracted to run RT-PCR reactions with human CFTR and B-actin primers; lanes 1-5 rSV40-CFTR, lanes 6-10 rSV40-BUGT. The 'no reverse transcriptase' controls were negative for both the CFTR and B-actin bands (data not shown).
Figure 7
Transduction of mucous-producing cells in the airways with rSV40. Mice received 1.5 Â 10 7 particles of an rSV40 vector with and AU1 epitope tag and were killed 9 weeks post-delivery. The far left frame is a hematoxylin-eosin (H&E) stain of the lung tissue, with black arrows depicting goblet cells. On the right are three fluorescence micrographs, the upper one using an antibody directed at lysozyme, to delineate the mucous-producing cells, the middle using an antibody against the AU1 tag, and the lower panels shows a merge of the two stains in which the white arrows show representative doubly positive cells. CFPAC cells are a pancreatic adenocarcinoma line that carries the most common known loss of function mutation in the CFTR gene: DF508. 18 The mutation causes an in-frame loss of a phenylalanine at position #508. The resulting abnormal protein can actually form a functional Cl channel, 26 but loss of F508 causes the protein to be misfolded and consequently shunted to the cellular proteosome for degradation, so it does not reach the cell membrane to serve as an ion channel.
Transduction with rSV40-CFTR delivered detectable CFTR protein by immunostaining in vitro and detectable transcription as determined by RT-PCR in vivo.
The in vitro studies also showed that rSV40 gene delivery transduced the great majority of cells in these cultures, without selection. This finding is consistent with previous data showing that at rSV40s can deliver transgene expression efficiently and do not require the use of a selective agent. 13 It is useful to point out that expression of proteins delivered by rSV40s, while permanent, tends to be at lower levels than are seen using other gene delivery vector systems.
Most importantly, treatment with rSV40-CFTR provided a functional chloride-channel activity that was lacking in both CFPAC and IB3 cells. Furthermore, channel function was shown by two different assays of Cl-channel activity, both of which showed similar functionality in the ion channel delivered by rSV40-CFTR. The level of Cl-channel activity in transduced cells was 1/3 to 1/2 of that seen in normal cells. Estimates of several investigators suggest that this level of Cl-channel activity is sufficient to avoid the most harmful consequences of mutation in CFTR. 27, 28 Thus, if the level of activity seen here could be achieved and maintained in vivo, it would be within the therapeutic range.
In vivo studies carried out in the bacterial agarose-bead model lend further evidence of the functional and corrective nature of the rSV40-delivered CFTR gene.
These results indicate that further study of the application of rSV40-CFTR to CF gene therapy is warranted. Indeed, these studies, conducted by instillation of rSV40-CFTR into airways of CFTR-knockout mice, suggest that this vector may be able to provide significant functional correction in vivo as well as in vitro. Our studies report a statistically significant difference in weight loss between our two groups: B26% for the BUGT-treated mice and B19% for the CFTR rescued mice at day 3. In comparison, the original study using the pseudomonasbead model by Van-Heeckeren et al. 21 reports a weight In our experiments, the weight loss was steeper and more prominent; this is probably because of the typical variability encountered in the preparations of the pseudomonas agar beads. However, one can appreciate that the difference in weight loss between groups was proportional in the two separate studies. More importantly for CF-related pathology, rSV40-CFTR rescue resulted in the reduction of KC and IL-1B, which correlated with the dramatic reduction of neutrophils influx to the lung and with a significantly improved overall inflammatory state of the lung as judged by histology.
CF gene therapy has stumbled at the transition between effective in vitro and in vivo gene delivery for many reasons. 4, 8, 29, 30 Applying rSV40 vectors to the treatment of CF may help address some of these issues: impermanence of transgene expression (rSV40s integrate and express their transgenes indefinitely), 12 cytolytic inflammatory responses against transduced cells (cells transduced with rSV40s do not elicit cytotoxic responses), 31 and need for repeat dosing (rSV40s, alone of all viral gene delivery vectors, do not elicit neutralizing antibodies). 16 Other questions, such as the best route of administration, 32 for example the most appropriate target cell, 33 are dilemmas that have stimulated considerable thought and experimentation, but that remain to be resolved. 10 Many hurdles remain before rSV40 gene delivery in CF and can reach clinical fruition. Many issues, including vector safety and appropriate production procedures, all need to be considered. The unique ability of rSV40s to avoid eliciting neutralizing antibody has been shown in rodents, 12, 13 but needs to be confirmed in higher animals. Finally, the route of delivery remains a major concern, as neither aerosolization nor instillation of other vectors through the airways has not yet yielded promising results. As SV40 is small (B40 nm in diameter), it may be delivered more efficiently to the lungs in CF patients through the vascular system. We have administered rSV40 vectors carrying marker genes intravenously and detected abundant transgene expression in the pulmonary airway epithelium. 34 Beyond questions of effectiveness, issues relating to vector safety are important. To date, our preparations of rSV40 vectors have been free of Tag+ revertant wtSV40. Animal recipients of these vectors have not shown evidence of adverse effects or toxicity. 13 Conventional therapies have improved survival for patients with CF dramatically. Interesting new approaches continue to offer benefits, or potential benefits, to some such individuals. 35 Some thoughtful approaches have recently been reported that may circumvent or decrease the barrier created by the airway inflammation and viscous mucous, so as to facilitate gene delivery. 36 However, gene therapy remains tantalizing, precisely because of its promise that CF treatment could one day actually give afflicted patients something approaching normal lives.
Whether rSV40 vectors make a contribution here remains to be seen. But our data suggest that they may provide an additional gene delivery option in treating CF.
Materials and methods pSV40(CFTR)
This vector uses a 4.2 kb (full-length) human CFTR cDNA paired to two tandem SV40-EP. rSV40 genome constructs reported to date lacked the 2.6 kb Tag and tag genes, but still carried the 2 kb of wtSV40 capsid protein genes, VP1, VP2, and VP3. As wtSV40 genome is 5.25 kb, deletion of additional SV40 sequences should allow effective packaging of a vector carrying a 4.2 kb version of the human CFTR cDNA. pSV5 contains a Tag-deleted SV40 genome with two tandem SV40-EP followed by an engineered polylinker. This modified SV40 genome was cloned as a NotI fragment in pGEM13. An additional 1.8 kb of wtSV40 DNA was excised from pSV5 as a HpaI Table 1 Gross pathology scores in CftrÀ/À mice 4 days after inoculation with pseudomonas-laden agarose beads
Vector treatment
Lung inflammation score and observations rSV40-CFTR 0 rSV40-CFTR 2 Multifocal, small, dilated airways surrounded by layer of PMNs and macrophages, exudate in lumens, minigranulomas rSV40-CFTR 0 rSV40-CFTR 0 rSV40-CFTR 2.5 Multifocal; bronchioles are surrounded by infiltrates, but rarely invaded Average score rSV40-CFTR 0.9* rSV40-BUGT 3.5
Major bronchioles invaded and disintegrating epithelium and alveolar cells, granulomas, bulli rSV40-BUGT 1.5 Multifocal mild infiltrates and epithelial damage rSV40-BUGT 2 Multifocal; bronchioles are surrounded by infiltrates but rarely invaded. rSV40-BUGT 3.5 Multifocal infiltrates-severe, rSV40-BUGT 3.5 Multifocal infiltrates-severe, mixed populations, 'casts'; airway epithelium disintegration with sloughting epithelium into the lumen; exudate in airway 'bulli rSV40-BUGT 2 Two foci infiltrates-mixed with PMN in lumen, numerous macrophages accumulating at point of infiltrate. Average score rSV40-BUGT 2.7* *Pp0.05 as determined by a Bonferonni-corrected Kruskal-Wallis Test. The following ranking system was used for inflammation: 0=normal; 1=mild, focal; 2=mild, multifocal; 3=moderate, multifocal; 4=severe, multifocal. Values are shown for each individual mice along with an average group score.
Restoring a functional Cl channel with rSV40(CFTR) C Mueller et al fragment to produce pSV5(D4.3). Human CFTR cDNA was cloned into the polylinker and SV(CFTR) was produced from this plasmid.
pSV(BUGT) and pSV(HBS)
This vector uses a human BUGT cDNA paired to two tandem SV40-EP and was used as a control vector for in vivo studies. pSV(HBS) was used as a control vector for in vitro studies.
Simian virus 40 vectors
The resulting Tag-less rSV40 genome, which is carried in pGEM13 (Promega, Madison, WI, USA), has been described. 12 pSV5(D4.3) was made by removing a 1.8 kb HpaI fragment from pSV5. pSVCFTR was made cloning a PCR product from hCFTR into pGEM-TEasy (Promega). A 5 0 primer containing an XhoI site (GGCTCGAGGG ACCCCAGCGCCCGAGAGA) and a 3 0 primer containing a SacII site (CACGTTCTATGTTCCGAAATTGG CGCCGG) were used to make a 4.5 kb PCR product containing the full-length CFTR cDNA. This fragment was then cloned into pGEM-TEasy, amplified, and the CFTR cDNA was cut out using SacII and XhoI. This fragment was then cloned into the SacII and XhoI sites in pSV5(D4.3) to make pSV5(CFTR). The procedures for making gene delivery vectors from cloned rSV40 genomes have been described in detail elsewhere. 17 Briefly, the SV(CFTR) viral genome was excised from this plasmid using NotI, gel purified, recircularized, and transfected into COS-7 cells. COS-7 cells, a simian kidney cell line immortalized by stable transfection with a wt SV40 genome that is deficient at the origin of replication, 16 were maintained in DMEM supplemented with 10% newborn calf serum (NCS, Hyclone). Virus was allowed to grow for 7 days after which lysates were harvested. Lysates were used to amplify SV(CFTR) by infecting COS-7 cells (ATCC, Washington, DC, USA), without helper virus and without additional transfections. Virus was purified by density centrifugation and virus stocks were titered by in situ PCR, as described previously. 17 To measure the infectivity of replicationdeficient SV-40, the viral stocks were titrated by in situ PCR. Infectivity of our rSV40 viral vector stocks was generally B10 9 IU ml -1 .
CFTR immunostaining
CFPAC cells, a CF pancreatic adenocarcinoma cell line (ATCC, #CRL-1918), 18 were maintained in Iscove's media supplemented with 10% NCS. Both media were supplemented with 2 mM L-glutamine and 1% penicillin-streptomycin and all cells were grown in 5% CO 2 and 100% humidity. The cells were plated in four-well slides at a density of 10 5 cells per well. The cells were transduced with rSV40-CFTR, rSV40-HBS (negative control), or were mock transduced. Cells were fixed in acetone-methanol (50:50) for 5 min. Blocking was performed by 1 h incubation with 10% goat serum. Cells were incubated for 1 h at room temperature with the primary antibody, mouse monoclonal anti-CFTR, C-terminus (Research Diagnostics, Inc., NJ, USA) at a 1:100 dilution, then washed three times with phosphate-buffered saline (PBS), and incubated with 1:100 diluted FITC-conjugated rabbit anti-mouse IgG (Dako, Carpinteria, CA, USA). Mounting medium containing DAPI (Vector Laboratories, Burlingame, CA, USA) was used to visualize the nuclei.
Chloride ion-channel activity mircoplate assay CFPAC cells were transduced with rSV40-CFTR at MOI ¼ 100 or mock transduced. Control cells were TC7 cells, which are normal simian kidney cells (courtesy, Janet Butel, Baylor College of Medicine). To measure Cl-channel activity, a microplate assay technique was used, as described by West and Molloy. 20 Specifically, 6 days after transduction with rSV40-CFTR, CFPAC cells were plated in 96-well culture plates at a density of 10 4 cells per well; 48 h after plating, cells were loaded overnight with 10 mM N-(6-methoxyquinolyl) acetoethyl ester. The following day, cells were washed with a chloride-containing buffer (2.4 mM K2HPO4; 0.6 mM KH2PO4; 10 mM HEPES; 10 mM dextrose; 1 mM MgSO4; 130 mM NaCl). This buffer was then replaced with a chloride-free buffer (2.4 mM K2HPO4; 0.6 mM KH2PO4; 10 mM HEPES; 10 mM dextrose; 1 mM MgSO4; 130 mM NaNO3) containing 10 mM forskolin. Repetitive fluorescence measurements were performed immediately using a Millipore Cytoflour 3050 plate reader (excitation; 360 nm, emission; 460). 36 Cl isotope tracer efflux assay IB3-1 cells were seeded at a density of 2 Â 10 6 cells per T25 flask in LHC-8+ and left overnight in a 37 1C humidified CO 2 incubator. The next day, monolayers had achieved subjectively between 60 and 70% confluence. T84 cells were also seeded as a supra-physiologic CFTRpositive control and allowed to grow to B70% at this time. The wells containing IB3-1 cells were assigned into either negative control plates that received PBS treatment or CFTR test plates that received either infected with viral rSV40-CFTR at an MOI of 100 (particles/cell). The virus-containing media (LHC-8+) was left on the cells until day 5 and then was changed with 10 ml of fresh LHC-8+ medium. The LHC-8+ medium was replaced again on day 8. On day 10, cells were loaded with 5Ci of 36 Cl for 5 h at 37 1C. Each flask was then transferred into a modified 37 1C dry heat incubator and placed on a metal block heat sink. Each flask was washed five times with lactated Ringers solution for 30 s per wash to remove excess isotope and the efflux rate was then measured at 30 s intervals for 4.0 min. All washes and the first efflux collection were obtained by removing the entire fluid volume (1.5 ml) from the flask with a disposable finetipped transfer pipette, and replacing an equal amount of 37 1C lactated Ringers solution. The replacement solution for second through eighth samples contained a combination of 2.5 mM forskolin, 250 mM 8-Br-cAMP, and 250 mM CPT-cAMP, added to increase intracellular levels of cAMP. At the conclusion of the final time point, the monolayer was carefully examined for integrity. Flasks with non-intact monolayers were eliminated from the experiment. Samples were mixed with CytoSafe scintillation fluid and counted for 36 Cl activity. Statistical analyses were conducted by a two-tailed t-test, P(Tpt). The percentage of change from the maximal post-agonist rate (c.p.m.) and the minimal rate (c.p.m.) before that efflux event is defined as the 'percentage of change in efflux'. Cells without significant CFTR activity will not stimulate on exposure to agonist mixture and will display a negative 'percentage of change in efflux'. Uninfected negative control IB3 cells ('IB3'), supra- 
Pseudomonas agarose-bead challenges
In the challenge experiments, CFTRtm1Unc-TgN (FABPCFTR)#Jaw mice (gut-corrected CFTR knockout mice) and (CFTRÀ/À ) mice were treated intra-trachealy with rSV40-CFTR vector or rSV40-BUGT vector or PBS, housed in specific pathogen-free conditions for 8 weeks, and then challenged with 30 ml of an B50% Pseudomonas agarose-bead mixture (as determined by 30-min gravity sedimentation) of OD600 2.0 containing B3.0 Â 10 6 cfu ml -1 . Mice were randomized with regards to injection to avoid any unrecognized systematic error. Weights were recorded at time of challenge and at time of killing on day 4. Histopathologic analysis of hematoxylin-eosin-stained sections of formalin-fixed, paraffinembedded lung tissue samples taken at the time of killing was performed by a pathologist blinded to the assignment of animals to the two groups.
RT-PCR for detection of hCFTR expression
To ensure the expression of hCFTR by the lungs, after intra-tracheal injections of rSV40-CFTR, lungs were collected from all the CFTRÀ/À mice. A 100 mg of tissue sample was used to extract mRNA using the Qiagen (Valencia, CA, USA) total RNA columns. For reverse transcriptase first strand synthesis, the Invitrogen Superscript III kit was used with the oligo(dt) primers and the optional DNase digestion according to the manufacture's protocol. This was followed by a PCR using Eppendorf Taq polymerase master mix and genespecific primers for hCFTR (hCFTRfor_5 0 aaacttctaatggtgatgacag, hCFTRrev_5 0 agaaattcttgctcgttgac) or B-actin (B-actin1_5 0 gctcgtcgtcgacaacggtc, Bactin2_5 0 caaacatgatct gggtcatcttctc). The no RT controls were subjected to the same PCR conditions and primers, but in the absence of reverse transcriptase in the initial cDNA synthesis.
Immunodetection of rSV-40 transduction
Mice were intra-trachealy injected with an rSV40 vector expressing an AU1 epitope tagged gene, 9 weeks postdelivery mice were killed and their lungs were inflated with a 50/50 mixture of PBS and OCT and subsequently frozen in OCT medium. For immunofluorescence, 10 mm cryostat sections were processed for indirect immunofluorescence. Blocking was performed by 60 min incubation with 10% goat serum in 0.10 M PBS (pH 7.4). Then, cryostat sections were incubated with mouse FITClabeled anti-AU1 (IgG2a; 1: 100) (Covance, Emeryville, CA, USA) FITC, and rabbit anti-human lysozyme (Accurate Chemical and Scientific Corp., Westbury, NY, USA). Incubation with primary antibody was performed for 1 h and followed by incubation for 1 h with secondary antibody TRITC-conjugated goat anti-mouse IgG (Sigma, Saint-Louis, MO, USA), diluted 1:100. Incubations were at room temperature. Double immunofluorescence was performed as described previously. 37 Incubation was followed by extensive washing with PBS. Specimens were finally examined under a Leica DMRBE microscope (Leica Microsystems, Wetzlar, Germany). For negative controls, slides were pre-incubated with PBS and 0.01% BSA, non-immune isotype-matches control antibody was substituted for primary antibody, and/or the primary antibody was omitted.
Lung BAL for cell differentials and cytokine profiles
The BAL fluid was retrieved from each animal through cannulation of the exposed trachea and gentle flushing of the lungs with two separate 1 ml aliquots of PBS. Aliquots were pooled for individual animals preceding centrifugation and separation of pelleted cells and supernatant. Cytospin cell preparations made with 200 ml of BAL were stained using Hema 3 (Biochemical Sciences, Swedesboro, NJ, USA) differential stain, and relative cell populations were determined using standard morphological criteria. Total cell numbers were calculated by counting the cells on the cytospin slide obtained from the 200 ml BAL aliquot. Assessments of cytokine profiles from the BAL were performed using a commercially available multiplexed kit (Biorad Mouse Multi-Cytokine Detection System; Bio-Rad Laboratories, Hercules, CA, USA) and the Bioplex Suspension Array System. Simultaneous measurement of several cytokines was performed. All assays were performed according to the manufacturer's protocols. Cytokine concentrations were determined using Bioplex software with fourparameter data analysis. The sensitivity of the assay is o10 pg ml -1 and has a range from 0.2 to 32 000 pg ml -1 with an inter-and intra-assay CV of o10%.
